SUMMARY
At the 2025 annual meeting of the European Society for Blood and Marrow Transplantation (EBMT), several impactful studies were presented that have important implications for transplant-eligible and post-transplant patient populations. Topics of this article include the prognostic value of early cytomegalovirus clearance, novel therapy for Epstein-Barr virus-positive post-transplant lymphoproliferative disease, the efficacy of post-transplant cyclophosphamide across donor types in acute lymphoblastic leukaemia, and updates on multiple myeloma, myelodysplastic syndrome, and sickle cell disease.
(BELG J HEMATOL 2025;16(4):181–5)
